IL22RA1

Xuan Yin1,2,3, Renhao Geng1,2,3, Junjun Chen1,2,3

  • 1Department of Tumor Biological Treatment, Changzhou, 213003, Jiangsu, China.

BMC cancer
|August 7, 2025
PubMed
概括

在结肠癌中高IL22RA1表达与预后不佳和T细胞透减少有关. 向IL22RA1可能为结肠癌患者提供新的免疫疗法策略.